BPC-157 Hair and Skin Changes: What the Evidence Actually Shows

Does BPC-157 regrow hair or change skin in people?

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice [1]. It is not an FDA-approved drug, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

The human studies on record tracked other outcomes. FDA's reviewers found no human study of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [1]. The research they identified used rectal enemas, injections into the knee, injections into the bladder wall, or intravenous infusion, and measured outcomes such as ulcerative colitis, knee pain, bladder symptoms, blood markers and vital signs [1][5][6][7].

A systematic review searched to June 1, 2026 for human studies of BPC-157 in orthopaedic and regenerative use. It found 3 studies with 30 patients in total, all of poor methodological quality, with overall certainty of evidence rated very low, and it concluded that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [3]. Its three studies covered knee pain, interstitial cystitis and an intravenous safety pilot [3].

What the animal wound-healing studies actually measured

The skin claims trace back to rodent work. In one set of experiments, PL 14736 (another name for BPC-157) was compared with PDGF-BB in sponge-implant granulation tissue in rats and in full-thickness excisional wounds in genetically diabetic mice. Both agents stimulated granulation tissue with similar selectivity, PL 14736 was the more active of the two at stimulating early collagen organization, and it stimulated expression of the early growth response gene egr-1 and its repressor nab2 in Caco-2 cells more rapidly than PDGF-BB [2].

A separate study examined angiogenesis in animal muscle and tendon healing. BPC-157 had no direct angiogenic effect on cell cultures, but in crushed and transected muscle and tendon it produced modulated angiogenesis with upregulated VEGF expression, which the authors linked to better healing [8]. That is muscle and tendon, not skin, and not hair follicle.

Another line of work is purely mechanistic. In rat tendon fibroblasts, BPC-157 dose- and time-dependently increased growth hormone receptor expression; when growth hormone was added to BPC-157-treated cells, proliferation increased and JAK-2, the downstream signal pathway, was activated [9]. Tendon fibroblasts are not dermal papilla cells, and no follicle was measured.

The VEGF link to hair is not a BPC-157 finding

In mice, transgenic overexpression of VEGF in outer root sheath keratinocytes strongly induced perifollicular vascularization, accelerated hair regrowth after depilation and increased the size of hair follicles and hair shafts; blocking VEGF with an antibody retarded hair growth and reduced follicle size [4]. Perifollicular vascularization rises during the growth phase and regresses during involution and rest [4].

That experiment shows that follicle blood supply matters for mouse hair growth. It says nothing about BPC-157. The VEGF finding for BPC-157 comes from muscle and tendon healing in animals [8]. How BPC-157 works in people is unknown: FDA reported that its molecular targets have not been identified and that its mechanisms 'remain poorly understood' [1]. The reported protective effects come from rat studies, not human trials [1].

The skin reactions reported to FDA

FDA searched its adverse-event database through December 4, 2025 and found 3 reports, all involving injectable BPC-157 [1]. One described injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; one described shortness of breath leading to an emergency room visit, with no other detail; and one described widespread skin and gum darkening that recurred when the person was re-exposed to a BPC-157 plus TB-500 'research' product [1]. FDA said it cannot tell whether BPC-157 caused any of these [1].

Two of the three reports involve skin: redness and swelling where the injection went in, and a generalized darkening of skin and gums. The darkening occurred with a combination 'research' product, so the report does not establish that BPC-157 darkens skin, and it does not rule it out.

What is known about safety, and what is not

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information; in the healthy-volunteer enema studies, headache and flatulence were the most frequent events [1]. FDA concluded there is insufficient clinical safety information to characterize the safety profile of BPC-157 [1].

FDA also noted animal toxicity signals. In 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1].

Can BPC-157 be applied to the scalp or skin?

FDA found no human pharmacokinetic data for BPC-157 given orally, subcutaneously, nasally or on the skin, and after rectal enemas the peptide was mostly not detectable in blood [1]. Whether a topical product delivers the peptide into skin or scalp has therefore not been measured in people.

The route question is also regulatory. On October 28, 2026 HHS filed a notice announcing a draft enforcement-discretion policy for six peptides including BPC-157, scheduled for Federal Register publication on October 30, 2026 with public comments open for two weeks after publication [10]. For BPC-157 the draft covers the acetate form in subcutaneous, intramuscular, oral or topical forms; nasal, rectal and intravenous routes are not listed, and oral forms would need documentation of adequate bioavailability [11]. The notice states the policy 'does not establish any rights for any person and is not binding on HHS or the public' [10]. It names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities, and BPC-157 is not on FDA's list for outsourcing facilities [10][12].

Is BPC-157 approved, and where does compounding stand?

No. BPC-157 is not an FDA-approved drug, and no approved product contains it in any country FDA searched [1]. FDA placed it in category 2, its list of bulk substances that may present significant safety risks when compounded, from September 2023 until April 22, 2026. It now sits in a separate 'nominated but withdrawn' table because the groups that nominated it withdrew, and it is not in the category FDA says it generally will not act against compounders for [13][14]. Removal was not a finding of safety [13].

FDA's stated concerns remain on that page: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', may have problems with peptide-related impurities and characterization of the active ingredient, and FDA 'has identified no, or only limited, safety-related information' for the proposed routes [13]. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation, but that advice is non-binding and adding it would require formal rulemaking [1][15]. FDA's reviewers had recommended against listing, citing poor chemical characterization, little information on safety and immunogenicity, insufficient evidence that it works for ulcerative colitis, and the existence of several approved drugs for that disease [1].

WADA names BPC-157 in S0 (non-approved substances), prohibited at all times in and out of competition [16].

How does BPC-157 compare with finasteride for hair loss?

There is no comparison. In two 1-year trials, 1,553 men with male pattern hair loss received finasteride 1 mg daily or placebo, and 1,215 continued into a second year; hair counts in a 5.1 cm2 area of balding vertex scalp rose by 107 and 138 hairs over placebo at 1 and 2 years (P<0.001) [17].

BPC-157 has no hair-loss trial of this kind, and the three human studies in the 2026 review had no control group [3].